Xeris Biopharma’s Q3 2026: Recorlev Sparks a Revenue Runway Toward a $1B Horizon

Ticker XERS kept a steady rhythm in the third quarter, delivering a top‑line story that could outgrow the single‑drug narrative. The company posted total revenue of about $107 million for the quarter, up roughly 44% year over year, with Recorlev — the leading contributor — generating more than $71 million in net revenue, up about 93% from a year earlier. For investors and analysts watching the EPS and earnings surprise dynamics, the message is plain: stronger revenue forecasts are reshaping expectations for the year and for 2030, as Xeris nudges its outlook higher and pivots toward a multi‑product growth engine.

In a market where “earnings surprises” often come from somewhere other than the top line, Xeris’s commentary on guidance signals a more confident path to profitability if the revenue momentum translates into operating leverage. The press release frames this as a company that is not merely growing; it is growing with intention across its portfolio, including Recorlev, Gvoke, and Keveyis, and it points toward a pivotal Phase 3 program for XP‑8121 and the Cornerstone study as near‑term catalysts.

What the numbers show

The headline figures are the centerpiece. Total revenue reached $107 million for Q3 2026, a 44% year‑over‑year improvement, signaling a strong top‑line trajectory beyond the early‑stage growth phase. Recorlev, the company’s growth engine, accounted for approximately $71.5 million of that revenue in the quarter, marking a sustained acceleration that the management team has attributed to an expanded commercial footprint and better patient access. The relative strength of Recorlev underscores a shift from a single product story to a broader revenue engine.

The management narrative emphasizes momentum across the company’s portfolio, noting that the momentum is not limited to Recorlev. Gvoke and Keveyis are highlighted as part of a diversified growth profile, which helps mitigate reliance on a single product and raises the odds of sustainable top‑line expansion over the next several years.

Importantly, Xeris raised its full‑year 2026 revenue guidance to a range of $395–$405 million, up from prior bounds. They also issued a longer‑range optimism: a 2030 revenue outlook above $1 billion, versus roughly $750 million previously cited. In plain terms, the company is signaling that it believes its growth trajectory is durable enough to support a multi‑quarter and multi‑product expansion that could eventually translate into meaningful profitability improvements.

Near‑term catalysts and the XP‑8121 pivot

The company highlighted ongoing progress on XP‑8121, with Cornerstone — its pivotal Phase 3 study — expected to begin by year‑end. If timely, that study could unlock an additional growth vector for XP‑8121 and position Xeris for potential market expansion within its therapeutic franchise. The combination of this late‑2026 initiation with the continued performance of Recorlev suggests Xeris is betting on a multi‑year growth arc rather than a one‑and‑done quarter.

The management commentary frames this as a disciplined exploitation of momentum across key products, not a reckless sprint toward a single milestone. In sector terms, that’s a narrative that often appeals to investors who are wary of “earnings surprises” that come from cost cuts or one‑time items rather than sustainable revenue growth.

What this could portend for XERS and peers

For Xeris, the revise‑up in revenue forecast and the forward‑looking trajectory into 2030 creates suspense around profitability milestones. If the top line continues to outpace consensus expectations and the company successfully scales operating margins as it adds volume across Recorlev and other products, the market could start pricing in a more durable earnings profile. In equity terms, that means the EPS narrative — while not yet front and center in the quarterly release — becomes increasingly relevant as the revenue forecast tightens and the company edges closer to profitability.

For sector peers in endocrine and rare disease, Xeris’s Q3 performance offers a case study in how a multi‑product approach can stabilize growth, reduce reliance on a single asset, and improve the odds of beating earnings expectations in a rising‑revenue environment. The emphasis on a Phase 3 program nearing enrollment and a clear line of sight to a forthcoming milestone is a reminder that pipeline progress does not exist in a vacuum; it interacts with commercial execution to influence stock performance, cost of capital, and competitive dynamics.

Quotes and tone from the executive suite

“As a biopharmaceutical leader in endocrine and rare diseases, our third quarter performance puts us on a new growth curve,” said John Shannon, Chairman and Chief Executive Officer of Xeris. “Net product revenue in the third quarter grew more than 43% year‑over‑year, led by Recorlev, where our expanded commercial team moved from build to yield and delivered record referrals and new patient starts.” The forward‑looking tone reinforces the thesis that the company expects this momentum to persist as Cornerstone moves toward pivotal status.

Shannon also noted accelerated progress on XP‑8121 and reiterated confidence in the plan to initiate Cornerstone by year‑end, a development that could have meaningful implications for both the near‑term revenue mix and the longer‑term growth trajectory. It’s a narrative that aligns a strong commercial engine with a late‑stage program, a combination that investors tend to reward when execution remains credible.

Earnings terms to watch (EPS, EPS consensus, revenue forecast, etc.)

While the release centers on revenue growth rather than segmentable earnings per share (EPS) today, analysts and investors will soon be aligning on EPS consensus for the period as the company updates its cost structure and potential profitability. In this context, a future earnings surprise could arise not just from higher revenue but from improved gross margins and operating leverage as Recorlev reaches scale.

Key terms to monitor include EPS and the EPS consensus as analysts model the impact of higher revenue, the cadence of sales and marketing investments, and any R&D spend tied to XP‑8121 and the Cornerstone program. The revenue forecast for 2026 and the longer‑range forecast to 2030 are the levers that will feed those models, and a sustained beat to estimates could prompt a re‑rating of the stock relative to its growth peers.

Where to hear more and what to listen for

Xeris scheduled a conference call and webcast for 8:30 a.m. ET on the day of the release. The listening points will likely include commentary on patient access, payer dynamics, and the trajectory toward net product revenue contributions across the portfolio. For observers, the call is a useful window into operating leverage expectations, potential margin improvements, and questions about the pace of XP‑8121 enrollment.

Bottom line and what it means for the sector

The Q3 2026 results place Xeris at a juncture where revenue growth becomes the primary narrative driver behind the stock’s valuation. The combination of a higher revenue forecast, a multi‑product growth story, and a near‑term Phase 3 catalyst provides a framework for investors to think about XERS not as a one‑drug play but as a developing ecosystem play within its niche. If the company can translate this top‑line momentum into sustainable profitability and meet or exceed its revised revenue forecast, the market could reappraise the stock alongside peers that are navigating similar trajectories—where the next few quarters are less about a single beat and more about the durability of a growth platform.

In short, the third quarter reads like a statement of intent: Xeris believes it can turn recent gains into a longer‑term revenue engine. The question for investors is whether the market accepts that the path to >$1B in revenue by 2030 is not a straight line but a series of deliberate steps—each step a potential catalyst and a test of the company’s ability to convert top‑line strength into earnings power.